Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Pharmacyclics
Pharmacyclics
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Finance
AbbVie to purchase Pharmacyclics for US$21bn
Gains access to cancer treatment Imbruvica
WuXi subsidiary in deal with Pharmacyclics
Supply arrangement follows approval of Imbruvica by US FDA
Manufacturing
Catalent to supply cancer drug capsules for commercial supply to Pharmacyclics
Following approval by the US Food and Drug Administration for the treatment of mantle cell lymphoma
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Blood cancers – ibrutinib
There is a need for new treatment options for patients whose treated chronic lymphocytic leukaemia or other B-cell malignancy has relapsed, or who do not respond to existing therapies
Subscribe now